: +852 2951 1988
: +852 2951 1999
: +852 5606 9390
: +852 5606 9390
Mainland residents pay at their own expense
Inoculation of COVID-19 Comirnaty Bivalent Vaccine
Vaccination plays a key role in preventing serious complications in infected patients. In view of this, there is a strong demand for the COVID-19 vaccine, and also the Comirnaty Bivalent Vaccine targeting the Omicron variant.
Recently, Comirnaty and Comirnaty bivalent vaccines have been officially registered as Hong Kong drugs/products (biological products).
Recently, Comirnaty and Comirnaty bivalent vaccines have been officially registered as Hong Kong drugs/products (biological products).
The Comirnaty bivalent vaccine is an iteration of and complement to the already-marketed Comirnaty vaccine. Preclinical data shows that the Comirnaty bivalent vaccine is effective against Omicron variant and the original wild-type virus strains after inoculation as a booster. Strong neutralizing antibody responses can be produced.
It is a very convenient choice for mainland residents to come to Hong Kong to receive the Comirnaty bivalent vaccine.
People suitable for inoculating the Comirnaty Bivalent Vaccine
Aged 18 or above, and
Have been inoculated at least 2 doses of any COVID-19 vaccines
Have been diagnosed with COVID-19 after 6 months
